A Phase 1b/2, Open-Label, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of SM88 in Patients With Prostate Cancer.

Trial Profile

A Phase 1b/2, Open-Label, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of SM88 in Patients With Prostate Cancer.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs SM 88 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Tyme Technologies
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results assessing biomarker activity after completion of dose escalating phase 1b presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2017 Results of phae Ib cohort II, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top